The action of ergotamine on the 5-hydroxytryptamine (5-HT) venous sensitivity was studied in ergotamine abuser and non-abuser migraine patients. Ergotamine abusers showed reduced 5-HT hand vein contraction during abuse, compared to seven days after ergotamine withdrawal. In non-ergotamine users, the 5-HT venoconstriction was not significantly modified 12 h after a single intramuscular ergotamine (0.25 mg) administration. Even the administration of ergotamine locally into the vein did not change the venospasm of 5-HT given acutely in the same vein. Therefore, it seems that the 5-HT antagonism does not contribute to the therapeutic effect of ergotamine during the migraine attack. Moreover, the reduced 5-HT responsiveness during ergotamine abuse may possibly be compatible with the chronic headache present in some abusers, the withdrawal headache attacks and the abuse itself.
SicuteriF.Headache as possible expression of deficiency of brain 5-hydroxytryptamine (central denervation supersensitivity).Headache1972;12:69–72.
2.
Muller-SchweinitzerEFanchampsA.Effects on arterial receptors of ergot derivatives used in migraine. In:CritchleyMFriedmanAPGoriniSSicuteriF edsAdvances in neurology.New York:Raven Press1982;33:343–56.
3.
SaxenaPR.Pharmacology of cranial arteriovenous anastomoses. In:OwmanCHardeboJE edsNeural regulation of brain circulation.Amsterdam:Elsevier Science Publishers BV1986:541–58.
4.
Muller-SchweinitzerE.Serotoninergic receptors in brain vessels. In:OwmanCHardeboJE edsNeural regulation of brain circulation.Amsterdam:Elsevier Science Publishers BV1986:219–34.
5.
OstergaardJRMikkelsenEVoldbyB.Effects of 5-hydroxytryptamine and ergotamine on human superficial temporal artery.Cephalalgia1981;1:223–8.
6.
HachinskiVNorrisJWEdmeadsJCooperPW.Ergotamine and cerebral blood flow.Stroke1978;9:594–6.
7.
LauritzenMOlesenJ.Regional cerebral blood flow during migraine attack by xenon-133 inhalation and emission tomography.Brain1984;107:447–56.
8.
PuzichRGirkeWHeidrichHRischkeM.Effect of ergotamine tartrate on extracranial cerebral vessels in migraine. A doppler ultrasound study. In:PfaffenrathVLundbergPOSjaastadO edsUpdating in headache.Berlin:Springer-Verlag1985;153–8.
9.
AndersenARTfelt-HansenPLassenNA.The effect of ergotamine and dihydroergotamine on cerebral blood flow in man.Stroke1987;18:120–3.
10.
FanciullacciMFranchiGSicuteriF.Ergotamine and methysergide as serotonin partial agonists in migraine.Headache1976;16:226–31.
11.
RichardsonBPEngelGBuchheitK-HHoyerDKalkmanHOMarksteinRThomsonC.Defective serotoninergic neurotransmission: a possible cause of migraine and a basis for the efficacy of ergot compounds in the treatment of attacks. In:LanceJW edRecent trends in the management of migraine.Cantor1987:9–21.
12.
SaperJRJonesJM.Ergotamine tartrate dependency: features and possible mechanisms.Clin Neuropharmacol1986;9:244–56.
13.
SicuteriFDel BiancoPLFanciullacciMFranchiG.II test della venocostrizione per la misura della sensibilità alia 5-idrossitriptamina e alle catecolamine nell'uomo.Boll Soc Ital Biol Sperim1964;40:1148–50.
14.
Del BiancoPLSicuteriF.Computerized venospasm: a method for exploring the neurovascular junction in man.J Pharmacol Meth1978;1:329–40.
15.
BerdeBSchildHO eds.Ergot alkaloids and related compounds.Handbook of experimental pharmacology 49.Berlin:Springer-Verlag1978.
16.
RoquebertJGreniéB.a2-adrenergic agonist and a1-adrenergic antagonist activity of ergotamine and dihydroergotamine in rats.Arch Int Pharmacodyn1986;284:30–7.
17.
SaxenaPRCairo-RawlinsWI.Presynaptic inhibition by ergotamine of the responses to cardioaccelerator nerve stimulation in the cat.Eur J Pharmacol1979;58:305–12.
18.
Tfelt-HansenP.The effect of ergotamine on the arterial system in man.Acta Pharmacol Toxicol1986;59(suppl III).
19.
Arneklo-NobinBOwmanC.Adrenergic and serotoninergic mechanisms in human hand arteries and veins studied by fluorescence histochemistry and in vitro pharmacology.Blood Vessels1985;22:1–12.
20.
ArnerMHogestattED.Contractile effects of nor-adrenaline and 5-hydroxytryptamine in human hand veins: a pharmacological receptor characterization.Acta Physiol Scand1986;128:209–17.
21.
PanconesiAAndreiniRDel BiancoPLFranchiGSicuteriF.In vivo characterization of serotonin receptors on hand vein.Pharmacol Res Comm1988;20:433–34.
22.
Muller-SchweinitzerERosenthalerJ.Ex vivo studies after oral treatment of the beagle with dihydroergotamine.Eur J Pharmacol1983;89:1–8.
23.
Van NuetenJMJanssensWJVanhouttePM.Serotonin and vascular reactivity.Pharmacol Res Comm1985;17:585–608.
24.
BradleyPBEngelGFeniukWFozardJRHumphreyPPAMiddlemissDNMylecharaneEJRichardsonBPSaxenaPR.Proposal for the classification and nomenclature of functional receptors for 5-hydroxytryptamine.Neuropharmacology1986;25:563–76.
SchlakeH-PGrotemeyerK-HHusstedtIWMullerU-St.Vascular and neurographic findings in headache patients under chronic ergot and dihydro-ergot treatment.Cephalalgia1987;7(suppl 6):430–1.
27.
SharbyTTfelt-HansenPGjerrisFEdvinssonLOlesenJ.Characterization of 5-hydroxytryptamine receptors in human temporal arteries: comparison between migraine sufferers and nonsufferers.Ann Neurol1982;12:272–7.
28.
De MaréesHWelzelDDe MaréesAKlotzUTiedjenKUKnaupG.Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing.Eur J Clin Pharmacol1986;30:685–9.
29.
Muller-SchweinitzerERosenthalerJ.Dihydro-ergotamine: pharmacokinetics, pharmacodyna-mics, and mechanism of venoconstrictor action in beagle dogs.J Cardiovasc Pharmacol1987;9:686–93.
30.
Muller-SchweinitzerE.Pharmacological actions of the main metabolites of dihydroergotamine.Eur J Clin Pharmacol1984;26:699–705.
